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Abstract
Background: Vascular calcifications such as arteriosclerosis, which is characterized by a calcificiation of the tunica
media, represent major comorbidities e.g. in patients with chronic kidney disease (CKD). An essential step during
the development of arteriosclerosis is the transdifferentiation/calcification of vascular smooth muscle cells (VSMC)
resembling osteogenesis. The matrix metalloproteinases (MMP)-2 and −9 were shown to promote these VSMC
calcifications and their inhibition is of therapeutic value to prevent arteriosclerosis in preclinical studies. Aiming for
an understanding of the underlying regulatory mechanisms of MMPs we here investigated, if the MMP-mediated
VSMC calcification involves altered signaling of the Wnt pathway, which is known to impact osteogenesis.
Methods: We used an experimental in vitro model of vascular calcification. Transdifferentiation/calcification of
murine VSMC was induced by elevated calcium and phosphorus levels. Calcification was assessed by calcium and
alkaline phosphatase measurements. Activation/activity of the gelatinases MMP-2 and MMP-9 was assessed by
conversion of fluorescence-labelled substrates. Activation of the Wnt pathway was analysed by a reporter gene
assay.
Results: Besides pro-calcifying culture conditions, also activation of Wnt signaling by a specific agonist (under
normal culture conditions) stimulated VSMC-calcification accompanied by enhanced expression and secretion of
the gelatinases MMP-2 and −9. Vice versa, recombinant MMP-2 and −9 induced a time-delayed activation of Wnt
signaling after 72 h in VSMC but showed no direct effects after 24–48 h. These effects were blocked by pharmacological
inhibition of MMPs or of Wnt signaling.
Conclusions: Our study suggests that the pro-calcifying environment in CKD induces Wnt signaling in VSMC which in
turn contributes to the induction of MMPs which then foster the development of arteriosclerosis. Thus, besides MMP
inhibition, the inhibition of Wnt signaling in VSMC might represent a therapeutic target for the prevention of
vascular calcifications.
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Background
Vascular calcifications are a clinical hallmark of ad-
vanced cardiovascular disease (CVD) in the general
population. Besides chronic kidney disease (CKD) also
hypertension, diabetes mellitus, dyslipidaemia, obesity
and smoking could contribute to the development of
vascular calcifications [1]. Calcifications are associated
with increased cardiovascular morbidity and mortality
from CVD, creating a major public health burden [2–5].
A well-known type of calcification is atherosclerosis
which is characterized by intimal plaque formation
and which could lead to infarction or ischemia. A
second type of calcification is arteriosclerosis or mön-
ckeberg’s sclerosis. Arteriosclerosis is characterized by
calcification of the tunica media which amongst
others could result in vessel stiffness and “pseudo”
hypertension [6]. Studies suggest that the mortality of
CKD patients is linked more to arterial stiffening, a
consequence of medial calcification, than to athero-
sclerosis [7]. The development of arteriosclerosis is
based on a process of biomineralization resembling
osteogenesis [8, 9]. This involves an extensive remod-
elling of the arterial extracellular matrix e.g. a chan-
ged composition of collagens, degradation of elastic
fibres and transdifferentiation of vascular smooth muscle
cells (VSMC) from a contractile to a chondroblast-like
phenotype [10]. Proteolytic matrix metalloproteinases
(MMPs) contribute to the remodelling of the extracel-
lular matrix e.g. by degradation of elastic fibers and
subsequent release of bioactive matrix fragments [11].
Further, MMPs were shown to exhibit also mitogenic
activities on cells including VSMC [12–14] and to pro-
mote calcium and phosphorus (Ca/P)-induced trans-
differentiation of VSMC in vitro [15]. Vice versa,
inhibition of MMPs exerts protective effects against
vascular calcification in experimental in vitro and in
vivo models [15]. Thus, increased matrix degradation
by MMPs could provide an early signal in the patho-
physiology of calcifications and inhibition of MMPs
could be of therapeutic value.
However, little is known about regulation of MMP
secretion by VSMC especially in arteriosclerosis. Earl-
ier studies on atherosclerosis demonstrated that the
cleavage of cell surface N-cadherin by MMP-9 causes
activation of the Wnt pathway in VSMC [16]. Inter-
estingly, Wnt signaling is known to impact osteoblast
development and to stimulate chondrogenic differenti-
ation in pericytes [6]. Thus, regulation of cellular dif-
ferentiation by Wnt/ß-catenin pathway is critical for
vascular homeostasis [17].
Besides using specific Wnt agonists and antagonists, we
therefore investigated whether stimulatory and inhibitory
effects of recombinant MMPs and MMP inhibitors, re-
spectively, involve altered Wnt signaling also in an in




The murine VSMC cell line (MOVAS-1) was purchased
from ATCC (ATCC® CRL-2797™) and cells were cultured
in a humidified atmosphere at 37 °C and 5 % CO2.
Standard culture medium consisted of DMEM with
862 mg/l L-alanyl-L-glutamine, 6 mmol/l glucose, 50 μg/
ml streptomycin, 50 units/ml penicillin, 0.2 mg/ml G418,
supplemented with 10 % heat-inactivated fetal bovine
serum (FBS; Biochrom, Berlin, Germany).
Induction of VSMC calcification
VSMC were grown in 12- or 24-well plates to ~90 %
confluency (day 0). Calcification was induced by a calci-
fication medium (CM) consisting of standard culture
medium supplemented with NaH2PO4 and CaCl2 to
final concentrations of PO4
3− (2.8 vs. 1.0 mmol/l) and
Ca2+ (2.7 vs. 1.8 mmol/l), respectively. Cells were treated
for up to 9 days as indicated and media were replaced
every 2–3 days.
To study their effects on VSMC calcification, the recom-
binant MMPs-2 and −9 (3 nM; BioTez, Berlin, Germany)
and the specific inhibitors for MMP-2 (MMP-2 inhibitor I;
10 μM; Merck Schwalbach, Germany), MMP-9 (MMP-9
inhibitor I; 1 μM; Merck) and both gelatinases (Ro28-2653;
1 μM; Roche Diagnostics GmbH, Penzberg, Germany)
were added to CM.
Quantification of VSMC calcification
The differently treated VSMC were decalcified with 0.1 N
HCl for 30 min. Calcium contents were determined as de-
scribed [18] by the o-cresolphthalein complexone method
and normalized to respective protein contents.
Enzymatic activity of alkaline phosphatase (ALP) as
a marker of VSMC calcification was assessed in
VSMC supernatants using the Quanti Blue reagent
(InvivoGen, San Diego, CA, USA) after 24 h of treat-
ment. ALP activities were normalized to total protein
contents.
Quantitative real-time reverse transcription–polymerase
chain reaction (RT–PCR)
To study effects of CM on Wnt5a expression and of
the Wnt agonist I on MMP-2 and MMP-9 expression
in VSMC, the cells were treated as indicated for 24 h
and total RNA was isolated with the RNeasy Mini Kit
(Qiagen, Hilden, Germany) and transcribed into
cDNA with the High Capacity RNA to DNA kit (Ap-
plied Biosystems, Foster City, CA, USA). The cDNA
concentrations were determined by a NanoDrop ND-
1000 device (NanoDrop Technologies, Wilmington,
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NC). Quantitative PCR using SYBR Green Master
Mix (Applied Biosystems) and subsequent melting
curve analysis was performed using the Mx3000p
system (Stratagene/Agilent Technologies, Waldbronn,
Germany). Relative RNA amounts were calculated
using the 2−ΔΔCt method and normalized to mRNA
expressions of the housekeeping genes YWAHZ (tyro-
sine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide) and HPRT (hypo-
xanthine-phophoribosyl transferase). The primers se-
quences were: Wnt5a: forward primer, 5′-CAAAT
AGGCAGCCGAGAGAC-3′, reverse primer, 5′-CTCT
AGCGTCCACGAACTCC-3′; MMP-2: forward pri-
mer, 5′-CAGGGAATGAGTACTGGGTCTATT-3′, re-
verse primer, 5′-ACTCCAGTTAAAGGCAGCATCT
AC-3′; MMP9: forward primer, 5′-AATCTCTTCTAG
AGACTGGGAAGGAG-3′, reverse primer, 5′-AGCT
GATTGACTAAAGTAGCTGGA-3′ (BioTez Berlin-
Buch GmbH, Berlin, Germany).
Fluorogenic MMP activity assay
Treatment dependent enzymatic activities of MMP-2
and MMP-9 in VSMC supernatants were measured by
cleavage of 0.01 mg/ml dye-quenched DQ-gelatin (Mo-
lecular Probes, Life Technologies GmbH, Darmstadt,
Germany) as described in detail earlier [18].
To determine effects of the Wnt inhibitor on enzym-
atic activities of MMP-2 and MMP-9, recombinant
MMP-2 and MMP-9 alone or mixed with the Wnt
inhibitor FH535 (10 μM; CAS 108409-83-2; Merck,
Schwalbach, Germany) were subjected to DQ-gelatin
measurements.
Transient transfection of VSMC and assessment of Wnt
activation
VSMC were transiently transfected with reporter plas-
mids (Promega, Mannheim, Germany) for the T-cell
factor (TCF)/lymphoid enhancer-binding factor (LEF)
binding motif (pGL4.49[luc2P/TCF-LEF RE/Hygro]) and
Fig. 1 Effects of calcification medium, Wnt agonist I and gelatinase inhibitors on Wnt activation, Wnt5a mRNA expression and calcification
of VSMC. a VSMC transfected with TCF/LEF-luciferase reporter plasmids were treated as indicated and luciferase activity as an indicator
for activation of Wnt signaling was measured. Data were normalized to a parallel transfected renilla reporter vector (n = 4). b Effects
of CM on the mRNA expression of Wnt5a were determined by qPCR measurements (n = 4) c VSMC were treated as indicated. Measurements
of calcium contents or alkaline phosphatase (ALP) activities in VSMC cultures served as markers for VSMC calcifications (n = 4). Shown
are means ± SD. nsnot significant to control, *P ≤ 0.05 (compared to control), **P ≤ 0.01 (compared to control), ***P ≤ 0.001 (compared
to control)
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a renilla vector (pGL4.74[hRluc/TK]) as described [18].
As a positive control for Wnt activation the Wnt agonist
I (CAS 853220-52-7; Merck, Schwalbach, Germany) was
used. To inhibit Wnt activation, the β-Catenin/TCF site-
inhibitor FH535 (10 μM; Merck) was used.
Statistical analyses
Data were analyzed by one-way ANOVA followed by the
Tukey post-hoc test using GraphPad PRISM, version
5.01 (GraphPad Software, San Diego, CA, USA) and dif-
ferences with P values ≤0.05 (*) were considered to be
statistically significant.
Results
CM-induced calcifications involve activation of Wnt signaling
in VSMC
In a first set of experiments we investigated whether a
calcifying environment alters the activation of Wnt sig-
naling in VSMC. As a positive control for Wnt activa-
tion, the transfected VSMC were treated with the Wnt
agonist I which caused a 10-fold higher activation of
Wnt signaling compared to control (Fig. 1a). Inter-
estingly, also treatment with CM induced a 2.5-fold
higher Wnt activation compared to control. Since
the gelatinases were previously shown to be involved
in VSMC calcification [15] and are also known to be
upregulated by CM, we additionally applied specific
inhibitors for MMP-2, MMP-9 or both gelatinases in
our experiments. As shown in Fig. 1a, all inhibitors
tend to reduce the CM-induced activation of Wnt
signaling in VSMC but only simultaneous inhibition
of both MMPs (Ro28-2653) provoked a significant
reduction.
Direct effects of the MMP inhibitors on Wnt signaling
were excluded by additional experiments showing no
interference of the inhibitors with Wnt activation by the
Wnt agonist (Additional file 1: Figure S1).
We additionally investigated the effects of CM on the
mRNA-expression level of Wnt5a, a protein involved in
Wnt signaling and calcification. As shown in Fig. 1b, CM-
treated VSMC exhibited a 3.5-fold enhanced Wnt5a-
mRNA expression compared to control.
Fig. 2 Effects of Wnt signaling on gelatinase gene expression and secretion and reverse effects of recombinant gelatinases on Wnt signaling. a VSMC
were treated for 24 h with the Wnt agonist I and gene expressions of MMP-2 and MMP-9 were determined by qPCR measurements (n = 3). b VSMC
were treated as indicated for up to 72 h. Gelatinolytic activities in aliquots of supernatants were determined by conversion of dye-quenched
(DQ)-gelatin substrate at indicated time points (n = 4). c VSMC transfected with TCF/LEF-luciferase reporter plasmids were treated as indicated
for 3 days and luciferase activity as an indicator for activation of Wnt signaling was measured. Data were normalized to a parallel transfected renilla
reporter vector (n = 4). Shown are means ± SD; nsnot significant to control, *P≤ 0.05 (compared to control), ***P≤ 0.001 (compared to control)
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Wnt-induced calcifications of VSMC involve enhanced
expression and secretion of MMP-2 and MMP-9
We next examined whether the stimulation of Wnt sig-
naling in the absence of CM was sufficient to induce
VSMC calcifications. Indeed, treatment of VSMC for 5
days with the Wnt agonist significantly induced elevated
calcium contents and enzymatic ALP activities in VSMC
cultures and VSMC supernatants, respectively. Both ef-
fects could be rescued most effectively by simultaneous
inhibition of MMP-2 and MMP-9 (Fig. 1c).
Since the gelatinases seemed to be involved in the
Wnt-mediated actions in VSMC, we consequently inves-
tigated effects of the Wnt agonist on the expression
levels of MMP-2 and MMP-9 in VSMC. Indeed, treat-
ment of VSMC with the Wnt agonist induced mRNA
expressions of MMP-2 (1.4-fold) and MMP-9 (2.3-fold)
(Fig. 2a) and also induced elevated gelatinolytic activities
in VSMC supernatants (Fig. 2b).
Vice versa, we also checked whether recombinant
MMP-2 and MMP-9 contribute to Wnt activation in
VSMC. Treatment of VSMC with recombinant MMP-2
or MMP-9 had no effect on Wnt activation in VSMC
during the first 24–48 h (Fig. 2c). However, a slightly
induced Wnt activation in VSMC treated with recom-
binant MMP-2 was observed after 72 h which was
blocked in the presence of the gelatinase inhibitor
Ro28-2653 (Fig. 2c).
Wnt agonist-induced effects can be blocked by specific
Wnt inhibition via TCF-sites
To investigate whether the Wnt-induced effects on
VSMC calcifications and MMP upregulations involve
TCF-sites, we repeated the previous experiments in the
presence of a specific β-Catenin/TCF site-inhibitor. As
expected, this inhibition of Wnt signaling blocked the
Wnt agonist I-induced Wnt activation (Fig. 3a) and the
calcification of VSMC cultures (Fig. 3b). Further, the
Wnt agonist-induced elevation of gelatinolytic activities
in VSMC supernatants were attenuated by specific in-
hibition of Wnt signaling (Fig. 3c).
Direct effects of the Wnt inhibitor on the enzymatic
activities of the gelatinases MMP-2 and MMP-9 were
excluded in fluorogenic MMP activity measurements
(Additional file 1: Figure S2).
Fig. 3 Effects of Wnt antagonism on Wnt agonist-induced Wnt activity, calcification and MMP-production in VSMC. a VSMC transfected with TCF/
LEF-luciferase reporter plasmids were treated as indicated for 3 days and luciferase activity as an indicator for activation of Wnt signaling
was measured. Data were normalized to a parallel transfected renilla reporter vector (n = 3). b VSMC were treated as indicated. Treatment
dependent calcium contents of VSMC cultures were determined by the o-cresolphthalein complexone method. (n = 4). c VSMC were treated
as indicated and gelatinolytic activities in aliquots of supernatants were determined by conversion of dye-quenched (DQ)-gelatin substrate (n = 3).
Shown are means ± SD, **P≤ 0.01, ***P≤ 0.001
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Wnt antagonism reduces CM-induced transcription of
MMPs and the calcification of VSMC cultures
The preceding experiments showed that CM induced
both, calcification and Wnt-signaling in VSMC. In
addition, a Wnt-agonist (to a lesser extent than CM) also
induced VSMC calcification. To verify these results, we
therefore finally investigated whether Wnt antagonism
interferes with CM-mediated effects in VSMC. Indeed,
Wnt antagonism significantly reduced the CM-induced
calcification of VSMC cultures. However, the measured
calcium and alkaline phosphatase contents were still sig-
nificantly upregulated compared to control treated cells
(Fig. 4a, b). Taking into account the results from Figs. 1a
and 2a, we assumed that this interference of Wnt antag-
onism with CM-induced calcification involves the alter-
ation of MMP transcription in VSMC. Indeed, the
presence of the Wnt-antagonist significantly reduced the
CM-induced upregulation of MMP-2 and in particular
of MMP-9 in VSMC (Fig. 4c).
Discussion
Recent studies have shown that aberrant Wnt signaling
is involved in vascular remodeling and calcification [17, 19].
We recently demonstrated an essential role of MMP-2 and
MMP-9 in the phenotypic transition of VSMC and the
development of uremic vascular calcification [15]. In the
present study, we demonstrate a functional link between
Wnt signaling and MMP expression in the process of calci-
fication of VSMC.
Pro-calcifying culture conditions induced Wnt signaling
in VSMC and Wnt agonist-induced Wnt signaling stimu-
lated VSMC to calcify even under normal (non-calcifying)
culture conditions. This clearly points to the fact that the
Wnt pathway in VSMC contributes to calcifications.
The Wnt-mediated effects in VSMC included the in-
duction of gene expressions of the gelatinases MMP-2
and MMP-9 which were recently shown to be strong
promoters of VSMC calcifications [15]. In addition, the
pro-calcifying culture conditions stimulated the tran-
scription of Wnt5a which is a non-canonical Wnt pro-
tein known to promote osteogenesis [20]. This points to
a transcriptionally regulated calcium/phosphorous-in-
duced Wnt-activation in VSMC which was also shown
by other studies where elevated phosphate concentra-
tions promoted β-catenin signaling [21].
Also a Wnt-induced MMP expression has been de-
scribed earlier, even if only in immune cells [22]. All the
above mentioned effects of Wnt signaling on calcifica-
tion and MMP expression were reduced by specific Wnt
antagonism via the TCF-site, suggesting a functional link
between Wnt signaling and MMP expression during vas-
cular calcification.
Fig. 4 Effects of Wnt antagonism on CM-induced VSMC calcification and MMP transcription in VSMC. VSMC were treated as indicated. Measurements
of calcium contents (a) or alkaline phosphatase (ALP) activities (b) in VSMC cultures served as markers for VSMC calcifications (n = 4). Shown
are means ± SD. nsnot significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. c VSMC were treated for 24 h with CM with or without the presence of the
Wnt antagonist FH535. The effects on mRNA expressions of MMP-2 and MMP-9 were determined by qPCR measurements (n = 3) Shown are
means ± SD, nsnot significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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Interestingly, simultaneous inhibition of MMP-2 and
MMP-9 reduced a CM-induced Wnt activation in VSMC
which suggested direct effects of MMPs on Wnt signaling
in VSMC. However, this assumption was disproved by
subsequent experiments showing that recombinant
MMPs had no direct effects on Wnt activation in
VSMC after 24–48 h.
Nevertheless, a link between enhanced proteolytic activ-
ity and enhanced Wnt signaling was brought up by the
fact that recombinant MMPs induced a (time-delayed) ac-
tivation of Wnt signaling in VSMC cultures after 72 h
which could by blocked by MMP-inhibition. One explan-
ation might be the generation of Wnt-stimulating matrix
fragments (such as elastin fragments) in VSMC cultures
due to enhanced proteolytic activity [11, 23]. This issue
demands further research in follow up studies.
A final set of experiments showed inhibitory effects of
Wnt antagonism on CM-induced VSMC calcification,
thus, confirming the contribution of Wnt signaling to
VSMC calcification. Wnt antagonism also reduced CM-
induced MMP expressions in VSMC which confirmed
that MMPs are regulated downstream of Wnt signaling
during VSMC calcification.
Conclusions
In summary, we here demonstrate that calcification
inducing culture conditions (elevated calcium and phos-
phorous levels) induce Wnt activation in VSMC which
then leads to enhanced expression of MMP-2 and MMP-9.
Thus, the present study and our previously published data
suggest the following hypothesis: in CKD, elevated serum
levels of phosphorus and/or calcium (amongst others)
may induce vascular calcifications by enhancing Wnt
activity in VSMC which entails enhanced MMP pro-
duction. The MMPs then further promote the process
of calcification [15].
We conclude that suitable inhibitors of Wnt signaling
and of MMPs might be of therapeutic value in the treat-
ment of vascular calcifications. Thus, they should be
applied alone or in combination to experimental models
of CKD-associated vascular calcifications to verify if our
in vitro data are of relevance in vivo.
Additional file
Additional file 1: Figure S1. It shows that direct effects of the MMP
inhibitors on Wnt signaling in VSMC could be excluded. Figure S2. It shows
that direct effects of the Wnt inhibitor on the enzymatic activities of the
gelatinases MMP-2 and MMP-9 in VSMC could be excluded. (TIF 186 kb)
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